• Policy
• Controversy rise over standards used in pricing negotiations
• by Moon, sung-ho Nov 11, 2021 06:00am

• Policy
• RWD & RWE will be important means of use in post-evaluation
• by Kim, Jung-Ju Nov 11, 2021 06:00am

• Policy
• The MFDS consulted on Expedite Approval of COVID-19 PO
• by Lee, Tak-Sun Nov 10, 2021 05:55am

• Policy
• The National Assembly speeds up the telemedicine bill
• by Lee, Jeong-Hwan Nov 10, 2021 05:55am

• Policy
• Moderna vaccine produced by SB has been applied
• by Lee, Tak-Sun Nov 9, 2021 05:53am

• Policy
• LG Chem seeks approval for its ‘Zemiglo+SGLT-2i’ combo
• by Lee, Tak-Sun Nov 9, 2021 05:53am

• Policy
• Will a recombinant flu vaccine be released in Korea, too?
• by Lee, Tak-Sun Nov 9, 2021 05:53am

• Policy
• "Reference pricing will activate sales of generic drugs"
• by Lee, Jeong-Hwan Nov 8, 2021 05:51am

• Policy
• Will RWD drive accessibility to ultra-high-priced drugs?
• by Kim, Jung-Ju Nov 8, 2021 05:51am

• Policy
• The introduction of a double price system is empty talk
• by Lee, Jeong-Hwan Nov 8, 2021 05:51am